DI DONATO, SAMANTHA
 Distribuzione geografica
Continente #
NA - Nord America 522
EU - Europa 344
AS - Asia 169
OC - Oceania 4
AF - Africa 3
Totale 1.042
Nazione #
US - Stati Uniti d'America 522
RU - Federazione Russa 175
HK - Hong Kong 46
SG - Singapore 46
IT - Italia 44
IE - Irlanda 40
CN - Cina 34
SE - Svezia 28
PL - Polonia 26
JO - Giordania 19
IN - India 12
ID - Indonesia 7
AT - Austria 5
CH - Svizzera 5
DE - Germania 5
AU - Australia 4
FI - Finlandia 4
CI - Costa d'Avorio 3
ES - Italia 3
GB - Regno Unito 3
AZ - Azerbaigian 2
NL - Olanda 2
NO - Norvegia 2
VN - Vietnam 2
AL - Albania 1
FR - Francia 1
IQ - Iraq 1
Totale 1.042
Città #
Santa Clara 239
Dublin 40
Hong Kong 38
Chandler 37
Fairfield 35
Singapore 33
Warsaw 26
Ashburn 21
Woodbridge 15
Lawrence 13
Florence 11
Moscow 11
Seattle 11
Altamura 10
Mumbai 9
Shanghai 9
Houston 8
Ann Arbor 7
Buffalo 7
Jakarta 7
Princeton 7
Rome 7
Boston 6
Cambridge 6
San Diego 6
Bern 5
Vienna 5
Boardman 4
Helsinki 4
Melbourne 4
New York 4
Wilmington 4
Abidjan 3
Barcelona 3
Beijing 3
Pune 3
Baku 2
Dearborn 2
Dong Ket 2
Kent 2
Los Angeles 2
Medford 2
Nanjing 2
Oslo 2
Pescara 2
Prad am Stilfser Joch 2
Redwood City 2
Taranto 2
Baghdad 1
Bagno a Ripoli 1
Brentford 1
Council Bluffs 1
Enshi 1
Falkenstein 1
Falls Church 1
Frankfurt am Main 1
Hefei 1
Hillsboro 1
Impruneta 1
London 1
Manassas 1
Munich 1
Naaldwijk 1
Norwalk 1
Tirana 1
Weitang 1
Yubileyny 1
Totale 704
Nome #
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 151
D20Serum metabolomic as biomarkers to differentiate early from metastatic disease in elderly colorectal cancer (crc) patients 141
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 98
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 96
Results of the observational prospective RealFLOT study 92
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 90
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 87
Exploring serum nmr-based metabolomic fingerprint of colorectal cancer patients: Effects of surgery and possible associations with cancer relapse 87
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough 61
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram 59
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 54
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer 49
Totale 1.065
Categoria #
all - tutte 3.994
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.994


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202022 0 0 0 0 0 0 0 0 2 1 19 0
2020/202178 13 4 12 7 2 5 4 11 2 13 2 3
2021/202244 0 0 6 1 1 0 2 5 1 1 13 14
2022/2023210 9 33 8 10 12 38 27 36 28 0 4 5
2023/2024100 2 7 9 6 6 19 0 24 5 6 9 7
2024/2025577 28 72 31 100 179 118 12 24 13 0 0 0
Totale 1.065